UPDATE: Credit Suisse Initiates Endocyte at Outperform Ahead of Catalysts

Credit Suisse initiated coverage on Endocyte, Inc. (NASDAQ: ECYT ) with a Outperform rating and a $16.00 price target. Credit Suisse noted, "We anticipate significant stock appreciation ahead of key events in early 2014, including a potential EU approval, pivotal Phase III data in ovarian cancer, and robust Phase II